SGP vs STAA
SGP: Spyglass Pharma is a clinical-stage biotech developing an innovative sustained-release drug delivery platform to improve patient outcomes in cataract surgery. STAA: STAAR Surgical designs and manufactures implantable collamer lenses (ICLs) for refractive vision correction, offering reversible alternatives to corneal refractive surgery.
Side-by-side fundamentals
| Metric | SGP | STAA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $20.54 | $24.71 | |
| Market cap as of 2026-07-23 | $682M | $1.2B | |
| Net margin as of 2026-07-23 | n/a | -7.2% | |
| Gross margin as of 2026-07-23 | n/a | +76.9% | |
| Operating margin as of 2026-07-23 | n/a | -9.1% | |
| ROE as of 2026-07-23 | -75.4% | -6.1% | STAA higher |
| ROA as of 2026-07-23 | -68.8% | -4.7% | STAA higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +4.0% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +0.0% | |
| Beta as of 2026-07-23 | 0.97 | 1.23 | |
| 1-year return as of 2026-07-22 close | -23.2% | +35.2% | STAA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.